Publications by authors named "J Wendler"
Diffuse intrinsic pontine glioma (DIPG) is a fatal central nervous system (CNS) tumor that confers a median survival of 11 months. As B7-H3 is expressed on pediatric CNS tumors, we conducted BrainChild-03, a single-center, dose-escalation phase 1 clinical trial of repetitive intracerebroventricular (ICV) dosing of B7-H3-targeting chimeric antigen receptor T cells (B7-H3 CAR T cells) for children with recurrent or refractory CNS tumors and DIPG. Here we report results from Arm C, restricted to patients with DIPG.
View Article and Find Full Text PDFBackground And Objectives: Radical prostatectomy is a standard treatment for prostate cancer, yet about 30% of patients experience rising biochemical markers within a decade post-surgery. Pelvic lymph node sampling during prostatectomy assesses potential lymph node metastases, but standard histological assessments, which typically examine only 2-3 tissue sections, often miss occult metastases. This study assesses the effectiveness of qPCR in detecting PSA coding KLK3 mRNA for identifying lymph node metastases post-prostatectomy and explores the correlation between PSA-mRNA and biochemical recurrence.
View Article and Find Full Text PDFBlunt abdominopelvic trauma frequently results in injuries to the urinary organs, especially in polytrauma. The urotrauma is rarely an acute life-threatening event; however, it may lead to severe complications. This review addresses the under-representation of urological trauma management in interdisciplinary medical training and its impact on patient outcomes.
View Article and Find Full Text PDFPolysorbates are the predominant surfactants used to stabilize protein formulations. Unfortunately, polysorbates can undergo hydrolytic degradation, which releases fatty acids that can accumulate to form visible particles. The detection and quantitation of these fatty acid degradation products are critical for assessing the extent of polysorbate degradation and the associated risks of particle formation.
View Article and Find Full Text PDFArticle Synopsis
- B7-H3 is a promising target for immunotherapy in pediatric solid tumors due to its limited presence in critical organs, leading to a phase I trial testing B7-H3 CAR T cells in young patients with tough-to-treat tumors.
- Sixteen patients participated in the trial, with no serious dose-limiting toxicities from the first CAR T cell infusion, and one patient showed a partial response after a second infusion.
- The study concluded that while B7-H3 CAR T cells were generally tolerable and had limited anti-tumor effects, a strong CAR T cell response may be needed for better outcomes, emphasizing the importance of the patient's immune environment.